SVRA | Savara Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.22 - 3.43
52 Week Range	2.8150 - 5.70
Beta	0.70
Implied Volatility	47.52%
IV Rank	3.28%
Day's Volume	988,003
Average Volume	1,350,543
Shares Outstanding	171,619,000
Market Cap	576,639,840
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-04-28

Valuation
Profitability
Growth
Health
P/E Ratio	-7.81
Forward P/E Ratio	N/A
EPS	-0.43
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	37
Country	USA
Website	SVRA

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

SVRA's peers: STOK, EWTX, CRNX, DYN, RVMD, IKNA, XLO, TARA, SRRK, VACC, FENC, XOMA, KZR, LBPH, TRDA, ANAB, ACLX, GPCR, AVTE, ALXO, RZLT, CYT, XOMAO, PTIX, TPST

*Chart delayed

Analyzing fundamentals for SVRA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see SVRA Fundamentals page.

Watching at SVRA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SVRA Technicals page.